novarti report strong group sale grew came
ahead consensu ep ahead
consensu expect strength pharma profit
ascrib continu competitor suppli issu
annualis one time write back inventori piqray
zolgensma post fda approv togeth account around half
margin uplift howev sandostatin lar gener may come sooner
expect recent approv uk germani compani
would drawn zolgensma sale ramp confid payer
fund quickli fall place demand strong novarti
recent launch need maxim combin strong
near-term readout due
made minim chang forecast ahead
guidanc fall within new updat guidanc rang neutral
rate reflect valuat execut risk term high risk
new launch team post departur paul hudson
catalyst risk zolgensma piqray uptak vs gener
eros afinitor sandostatin lar clinic trial entresto pef heart
failur po peak ofatumamab ms po
fevi asthma po
valuat novarti trade pe premium global
peer novarti trade ev/npv vs eu peer
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novarti provid healthcar solut compani
multi-national group compani special research
develop manufactur market rang healthcar
product led pharmaceut
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
scenario base pipelin success
higher peak sale cosentyx stronger sandoz
biopharma revenu gilenya patent life
extens
grey scenario base pipelin success lower
peak sale entresto lower cosentyx peak sale
lower sandoz growth
price rel chart measur perform swiss market
ind close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
figur novarti summari vs cs consensu
alcon discont op
share fd
chang forecast
made minim chang forecast
fulli dilut share
fx impact sale
sale
mid high singl digit
line last year
mid- high singl digit cer
fx impact op incom
net financ adj alcon/ab
op incom
op incom
end
alreadi use
novarti premium/ discount eu
novarti premium/ discount global
data file
 novarti
asthma
proof concept
highlight continu oper
sale opinc guidanc increas year
sickl cell file prv
derm cosentyx yoy ahead market nbrx gain nrbx
rheumatolog cosentyx yoy ahead market nbrx gain share
uniqu data area
product evid axial manifest patient axial
data later year come year addit indic
continu acceler use continu get strong recommend key
paragon-hf hfpef data expect esc septemb
seen strong demand approv may
first us patient treat june first intern patient treat french atu
commerci plan repres commerci live medicaid plan
commerci plan repres commerci live sign letter
intent contract term
therapi therapi within hour approv
major polici line/clos label common limit copi
combin use spinraza
polici place often work-around
almost patient approv go novarti hub
wide rang patient treat term age weight prior treatment
initi fda discuss intrathec dose older popul
eu japan approv infant expect countri file
pre-symptomat iv updat data world muscl societi oct
strong type updat data world muscl societi oct
global type iv us eu updat data eu paediatr neurolog societi
updat come autumn
payer coverag us
trial start abc tnbc trial start head neck
full rang rm indic medicin activ spm data specif
neurologist wile prescrib mayzent base survey data
live prefer access mayzent
work use digit tool find spm patient would benefit msprodiscuss
us approv launch expect
commerci medic team hire train
talon head head brolucizumab vs aflibercept includ clinic
dri eye signific unmet need patient us accur
diagnos treat appropri
re-invest medicin salesforc dtc campaign educ
expand part access
sickl cell vaso occlus crise primari caus pain
entresto paragon-hf pef novel endpoint recur heart failur
treatment gap sever asthma need someth beyond inhal therapeut
marie-fr tschudin appoint presid
join novarti head pharma europ
year industri year celgen
member exec committe novarti
pharma core margin cc favour one-tim item inventori
sale revis upward grow mid-high singl digit
pharma divis revis upward grow mid-high singl digit
sandoz revis upward broadli line low singl digit growth
opinc revis upward expect grow low doubl digit mid-teen
growth driver headwind continu core opinc vs py
innov medicin growth driver launch uptak increas
potenti resolut valsartan competitor suppli shortag
expect gener headwind might also see less headwind
earli tell
currenc impact mid-juli rate remain constant rest year
 zolgensma inventori indic label expans sprint timelin
zolgensma expens immedi product product prior approv
approv inventori written releas product approv roughli
zolgensma piqray product go extrem well readi suppli
mani patient indic sale expect long shelf life product
manufactur facil north carolina chicago acquir facil colorado
current capac patient expand cover exist label
pre symptomat phase affect file strong trial novarti go fda
agre file strategi aspir file year
 paragon/ofatumumab data hous publish via press releas
data hand excit see near futur issu press releas
case case basi submit paragon abstract hold late break session esc
 gilenya updat gener
expect gener launch novarti grant motiv prohibit
launch decis patent earliest march expect appeal earli
vigor defend dose patent
 paragon entresto qaw fevipipr higher odd posit
differenti trial paragon higher likelihood success numer
fail hf treatment popul learn trial actual
incorpor learn paragon cv mortal hospitalis primari endpoint
fevi lower likelihood asthma unmet need current biolog oral
beyond inhal extens program vibrant close pt
 perform expect follow access win confid posit
strong underli demand uniqu profil robust data- present data later
year prevent later year nraxspa put strong posit payer
focu new entrant held formulari posit focu go forward
 launch zolgensma mani pt treat
give specif number sale say strong demand rx come
hub steadi week wee line plan convers rx
system medicaid privat approv medic except polici ultim
ship sale recognis
 differ would gener impact higher end
rang given core op growth difficult get mid-point rang even
gener eros would take rang
great momentum expect key growth driver continu well ahead
expect start see gener impact eu countri see earli sign
rigor defend product inventori one happen saw acceler
sale momentum compar base effect
 provis case anticip chang corpor integr agreement
comment legal case
 zolgensma guidanc full year newli launch
focus fundament get pt preval pool newli diagnos
see result feel good trajectori
 rebat reform thought assess risk us reimburs price
environ fluid difficult predict propos ultim prevail hard
comment specif seen anyth paper propos legisl novarti
remain support mani reform transparency/access biosimilar/part b/oop part
highlight low exposur vs peer group leader ex-u europ
 margin innov medicin mid think conserv
quarter margin volatil last year margin good progress
rang good progress depend gilenya defenc confid
part origin guidanc potenti upsid earli updat guidanc
launch seen good progress overal highli confid product effort
 piqray sale take longer sale build
sale report solid start approv cdx includ nccn
engag payer cover target popul focu test
say test go expect continu
 zolgensma strong recept pt per week conserv
provid specif plural rang solid uptak everi week posit everi
week term pt plan polici contract
 paragon studi clear success/failur would releas top line pr
result sometim difficult interpret subgroup endpoint depend result
pr releas await secondari endpoint sub studi
 mayzent duplic gilenya first year sale approx
physician identifi pt spm lack therapi market focu
year educ launch far seen neurologist will
prescrib made progress access live confid long term
 entrestro behind sequenti acceler europ guidelin trigger us
strong momentum overal due underli demand new data open
hospit administr europ us china good start esc consensu
posit use endors product confid
 beovu colour us commerci oper
strong commerci team deep experi retin diseas field forc
deploy msl time plan place contract buy bill model
work patient seamless hcp get pt medicin ex-u gear
 sandoz divis growth back posit see improv area
base effect sustain
pleas perform mostli ex-u strong biosimiliar perform
gener us challeng environ base busi declin mid-teen
consist past quarter stabilis
 sandostatin lar europ countri gener approv timelin eu
one gener compani approv via decentralis procedur uk denmark
germani limit commerci activ far novarti close monitor us updat
model eros similar biosimiliar
 gilenya still accru royalti mitsubishi
novarti still pay accru royalti accord contractu term
 zolgensma progress ex-u
ex-u franc patient/ fulli paid self gov term ex-u approv
expect end
 tax rate go due mix effect keep go
tax rate slight increas confid remain year swiss tax
reform got approv basel feder level good plan secur take away
uncertainti attract tax rate overal get difficult year year expect
main attract rate mid-term
 cosentyx come script trend inventori affect price negoti donut
small differ sale rx trend mostli driven inventori noth import
flag regard momentum us
 paragon would characteris clean win secondari endpoint region
success base primari endpoint cv event hospitalis focu
burden hospitalis also repeat hospitalis look previou studi
particularli look eastern european less patient russia/georgia
taken consider sub-studi look cognit impact overal ae report
patient experi seen signal current spontan far
 perform humira biosimilar eu
high number market entrant competit market place seen solid uptak
adalimumab biosimilar tender penetr around vs origin rank
vs biosimilar player proud rituximab etanercept favour vs
 gross margin innov medicin flat yoy would good guid strong
specif new launch posit offset gener launch
much compar
 lutathera quarter quarter slow bit longer term growth
sale major sale us growth rate slightli declin major
tier centr work preval pool late line patient focus
posit treatment expect continu growth us ex-u sale recent got
spain/itali reimburs approv switzerland israel
 china impact tender gleevec
gener focus launch newer medicin entresto cosentyx strong start
expect tender affect gleevec futur moment signific impact launch
expect off-set futur impact
 expect use
show prevent voc expect posit patient popul
voc per year account total popul
 entresto updat reimburs china
work region level nrdl list nation upcom cycl alreadi
list region level goal nation list
 xiidra lack progress could appli aimovig
aimovig clariti field forc work impact pleas uptak
aimovig outsid us
 mayzent updat set coip screen
use hub system lab data genotyp deliveri product hub
encourag board month free work acceler feedback
ex-u momentum realli strong boost pioneer data
administr encourag perform china
 xiidra highlight expect sign part expans earlier
product reduc sign symptom rx market
excel commerci coverag part happen lock room
grow promot sensit dtc campaign
 zolgensma view medicaid
four polici medicaid encourag medic except request seen posit
respons first patient medicaid patient abl navig medic except
work system whilst polici set like acceler get polici
place longer medicaid privat
 zolgensma time dosag reimburs us vs global
parti recognis revenu immedi take provis rebat
time period contract model lag similar situat outsid
 refer price averag sell price bulk pharma product us vs europ
limit exposur part best ask competitor respect part take
account rebates/govern subsidiari net price major medicin recent
launch approach price top eu countri higher variabl part drug
 margin get target earli alreadi could take
right goal get get full year sooner give
updat dont view key lever achiev use driver margin
charl martineau pm univers toronto improv increas need data scienc improv hope transform
 program grow compani
basic number share
fulli dilut number share
compani mention price
